Login to Your Account



Other News To Note


Friday, July 6, 2012
• Optimer Pharmaceuticals Canada Inc., of Toronto, a unit of Optimer Pharmaceuticals Inc., said Canadian regulators approved Dificid (fidaxomicin) for the treatment of Clostridium difficile infection in patients 18 and older. The product, a macrocycle antibiotic, gained approval in the U.S. last year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription